Polycystic ovary syndrome is a risk factor for type 2 diabetes: results from a long-term prospective study
- PMID: 22698921
- PMCID: PMC3425413
- DOI: 10.2337/db11-1360
Polycystic ovary syndrome is a risk factor for type 2 diabetes: results from a long-term prospective study
Abstract
Polycystic ovary syndrome (PCOS) recently has been identified as a risk factor associated with type 2 diabetes. However, the evidence derives from cross-sectional observational studies, retrospective studies, or short-term prospective studies. This long-term prospective study of a large cohort of women with PCOS, followed from youth to middle age, aimed at estimating, for the first time, the incidence and potential predictors of type 2 diabetes in this population. A total of 255 women with PCOS were followed for at least 10 years (mean follow-up 16.9 years). Six women were patients with diabetes at baseline, and another 42 women developed type 2 diabetes during the follow-up. The incidence rate of type 2 diabetes in the study population was 1.05 per 100 person-years. The age-standardized prevalence of diabetes at the end of follow-up was 39.3%, which is significantly higher with respect to that of the general Italian female population of a similar age (5.8%). The likelihood of developing type 2 diabetes significantly increased as BMI, fasting glucose, and glucose area under the curve at baseline increased and significantly decreased as sex hormone-binding globulin (SHBG) levels at follow-up increased. This study demonstrates that the risk of type 2 diabetes is markedly elevated in middle-aged women with PCOS and suggests including BMI, glucose, and SHBG-circulating levels in the risk stratification.
Similar articles
-
Comprehensive Evaluation of Type 2 Diabetes and Cardiovascular Disease Risk Profiles in Reproductive-Age Women with Polycystic Ovary Syndrome: A Large Canadian Cohort.J Obstet Gynaecol Can. 2019 Oct;41(10):1453-1460. doi: 10.1016/j.jogc.2018.11.026. Epub 2019 Feb 1. J Obstet Gynaecol Can. 2019. PMID: 30712903
-
Progression of glucose intolerance and cardiometabolic risk factors over a decade in Chinese women with polycystic ovary syndrome: A case-control study.PLoS Med. 2019 Oct 25;16(10):e1002953. doi: 10.1371/journal.pmed.1002953. eCollection 2019 Oct. PLoS Med. 2019. PMID: 31652273 Free PMC article.
-
Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women.J Clin Endocrinol Metab. 1999 Jan;84(1):165-9. doi: 10.1210/jcem.84.1.5393. J Clin Endocrinol Metab. 1999. PMID: 9920077
-
Type 2 diabetes and cardiovascular disease in polycystic ovary syndrome: what are the risks and can they be reduced?Diabet Med. 2010 May;27(5):498-515. doi: 10.1111/j.1464-5491.2010.02994.x. Diabet Med. 2010. PMID: 20536945 Review.
-
Glucose intolerance states in women with the polycystic ovary syndrome.J Endocrinol Invest. 2013 Sep;36(8):648-53. doi: 10.1007/BF03346757. J Endocrinol Invest. 2013. PMID: 24105073 Review.
Cited by
-
Complications and challenges associated with polycystic ovary syndrome: current perspectives.Int J Womens Health. 2015 Jul 31;7:745-63. doi: 10.2147/IJWH.S70314. eCollection 2015. Int J Womens Health. 2015. PMID: 26261426 Free PMC article. Review.
-
The genetic susceptibility profile of type 2 diabetes and reflection of its possible role related to reproductive dysfunctions in the southern Indian population of Hyderabad.BMC Med Genomics. 2021 Nov 16;14(1):272. doi: 10.1186/s12920-021-01129-0. BMC Med Genomics. 2021. PMID: 34784930 Free PMC article.
-
Is there a Relationship between Serum IGF-1 and Thyroid Nodule, Thyroid or Ovarian Volume in Polycystic Ovarian Syndrome?Acta Endocrinol (Buchar). 2021 Apr-Jun;17(1):138-146. doi: 10.4183/aeb.2021.138. Acta Endocrinol (Buchar). 2021. PMID: 34539923 Free PMC article.
-
Suitability of the National Health Care Surveys to Examine Behavioral Health Services Associated with Polycystic Ovary Syndrome.J Behav Health Serv Res. 2018 Apr;45(2):252-268. doi: 10.1007/s11414-016-9543-6. J Behav Health Serv Res. 2018. PMID: 27966057 Free PMC article.
-
Alterations in Glucose Effectiveness and Insulin Dynamics: Polycystic Ovary Syndrome or Body Mass Index.Horm Res Paediatr. 2017;87(6):359-367. doi: 10.1159/000471804. Epub 2017 May 5. Horm Res Paediatr. 2017. PMID: 28478437 Free PMC article. Clinical Trial.
References
-
- Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004;19:41–47 - PubMed
-
- Gambineri A, Pelusi C, Vicennati V, Pagotto U, Pasquali R. Obesity and the polycystic ovary syndrome. Int J Obes Relat Metab Disord 2002;26:883–896 - PubMed
-
- Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev 1997;18:774–800 - PubMed
-
- Poretsky L, Cataldo NA, Rosenwaks Z, Giudice LC. The insulin-related ovarian regulatory system in health and disease. Endocr Rev 1999;20:535–582 - PubMed
-
- Bremer AA, Miller WL. The serine phosphorylation hypothesis of polycystic ovary syndrome: a unifying mechanism for hyperandrogenemia and insulin resistance. Fertil Steril 2008;89:1039–1048 - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous